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Measuring multimorbidity beyond counting diseases: systematic 
review of community and population studies and guide to  
index choice
Lucy E Stirland,1,2 Laura González-Saavedra,3 Donncha S Mullin,2,4 Craig W Ritchie,1,2  
Graciela Muniz-Terrera,1,2 Tom C Russ1,5,6
AbstrAct
Objectives
To identify and summarise existing indices 
for measuring multimorbidity beyond disease 
counts, to establish which indices include 
mental health comorbidities or outcomes, and to 
develop recommendations based on applicability, 
performance, and usage.
Design
Systematic review.
Data sOurces
Seven medical research databases (Medline, Web of 
Science Core Collection, Cochrane Library, Embase, 
PsycINFO, Scopus, and CINAHL Plus) from inception 
to October 2018 and bibliographies and citations 
of relevant papers. Searches were limited to English 
language publications.
eligibility criteria fOr stuDy selectiOn
Original articles describing a new multimorbidity 
index including more information than disease counts 
and not focusing on comorbidity associated with one 
specific disease. Studies were of adults based in the 
community or at population level.
results
Among 7128 search results, 5560 unique titles were 
identified. After screening against eligibility criteria 
the review finally included 35 papers. As index 
components, 25 indices used conditions (weighted 
or in combination with other parameters), five used 
diagnostic categories, four used drug use, and one 
used physiological measures. Predicted outcomes 
included mortality (18 indices), healthcare use or 
costs (13), hospital admission (13), and health 
related quality of life (7). 29 indices considered 
some aspect of mental health, with most including 
it as a comorbidity. 12 indices are recommended for 
use.
cOnclusiOns
35 multimorbidity indices are available, with 
differing components and outcomes. Researchers 
and clinicians should examine existing indices for 
suitability before creating new ones.
systematic review registratiOn
PROSPERO CRD42017074211.
Introduction
Multimorbidity, usually defined as the coexistence of 
two or more chronic conditions within an individual, is 
important for patient outcomes and healthcare costs. 
Because its prevalence is rising as populations age, 
multimorbidity is attracting increasing attention from 
the research community worldwide.1 More than 2800 
publications on multimorbidity appeared between 
1900 and 2016, 80% of which were published after 
2010.2 As no universally agreed measure or list of 
diseases exists to define multimorbidity, numerous 
indices have been developed. These might be designed, 
for example, to quantify multimorbidity as a covariate 
in other analyses, for mortality prediction or for risk 
adjustment. Previous systematic reviews identified 
multiple indices, but no searches have been done of 
indices since 2009.3 4
Multimorbidity research most often refers to a 
count of chronic conditions.4 This method does not 
reflect patients’ experience or the effects of different 
combinations or severity of diseases.5 Some indices, 
however, combine disease counts with severity mea­
sures, physiological factors, or demographic items, 
thereby allowing a more holistic quantification of 
illness burden.
The coexistence of both physical and mental 
illness within multimorbidity is prevalent.6 A 2018 
report identifying priorities for multimorbidity 
research highlighted the need for more work into this 
coexistence.1 Researchers exploring multimorbidity 
will therefore increasingly need to account for mental 
disorders. As previous reviews of multimorbidity 
indices have not covered mental health in depth we 
identified and summarised all community based 
multimorbidity measures that include more than 
simple disease counts, paying particular attention 
to mental health. This review should help guide 
clinicians and researchers to select an appropriate 
index according to their requirements.
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WhAt Is AlreAdy knoWn on thIs topIc
It is common for people to have two or more co-occurring chronic conditions 
(multimorbidity)
Researchers and clinicians use many different indices to measure multimorbidity
WhAt thIs study Adds
At least 35 objective measures of multimorbidity are available for people living in 
the community and each of these uses different variables to generate a score or 
index, linked with various or no outcome measures
No specific index investigates the interplay between mental and physical 
multimorbidity, although this is dealt with in a variety of ways across the 
measures
The recommendations in this study should guide researchers to find a suitable 
index for their purposes
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Methods
No single accepted term describes the methods of 
measuring multimorbidity. In this review we use the 
term “index” to refer to any method of quantifying 
disease burden or predicting specific outcomes that 
includes more than a count of conditions. This could 
be by weighting conditions (for example, by allocating 
a score to each), adding other elements, or exa­
mining other variables such as drug or physiological 
parameters.
search
To capture all relevant publications we conducted 
a broad search. We included a variety of terms for 
multimorbidity derived from previous systematic 
reviews on this topic3 4 and other literature discussing 
terminology in this area of research.7 We developed 
the search strategy iteratively with the support of an 
Academic Support Librarian. The final search terms 
are listed in the appendix (appendix eTable 1) and 
include multimorbidity, comorbidity, polypathology, 
polymorbidity, pluripathology, multi­condition, and 
multiple chronic conditions. The search was restricted 
to adults older than 18 years and to English language 
publications.
eligibility criteria
We planned to summarise reports of novel indices and 
were primarily interested in the original report of each 
index. Therefore we excluded papers that either used 
existing indices or measured multimorbidity using 
only disease counts. In the initial screening process 
we included only the original form of each scale and 
not adaptations or updates; these were found later. 
Records that were not original research papers, such as 
conference abstracts, letters, and systematic reviews, 
were excluded. We defined multimorbidity as multiple 
co­occurring conditions without reference to a specific 
disease, so excluded papers were those that focused on 
comorbidities of an index disease or on comorbidities 
within one disease area (such as the coexistence of 
several psychiatric conditions). As most people with 
multimorbidity are adults living in the community and 
managed in primary care, we excluded articles about 
children, animals, or people admitted to hospital 
or living in residential care. We included studies of 
hospital inpatients when the primary focus was follow­
up after discharge (for example, mortality one year 
later). As resources were limited, we excluded papers 
when full texts were not available in English.
information sources
On 19 October 2018 we searched Medline, Web of 
Science Core Collection, Cochrane Library, Embase, 
PsycINFO, Scopus, and CINAHL Plus from inception 
onwards.
study selection
Two authors used Covidence software independently 
to screen titles against exclusion criteria and the 
subsequent abstracts against the same criteria.8 We 
then extracted the full texts of relevant abstracts 
for further screening. Any disagreements at the 
title, abstract, and full text stages were resolved by 
discussion, and a third author mediated unresolved 
conflicts. We excluded papers that referred to an 
existing index, but listed the indices that were used 
when excluding them at the abstract stage. We found the 
original papers describing these indices and returned 
them to the title screening stage. Additional relevant 
titles were found by reviewing previous systematic 
reviews on this topic, searching the bibliographies of 
included full text papers, and tracking their citations 
using Google Scholar. Emerging relevant titles were 
added to the screening process.
usage, updates, and validation
After the list of included papers had been finalised, we 
searched their citations on Google Scholar for updates, 
revisions, or adaptations as well as validation papers. 
When original indices were adapted and validated 
numerous times, we listed the original performance and 
principal adaptations. We did not include adaptations 
where the original index was translated into another 
language with no other changes made. To assess the 
popularity of each index, we took the total number of 
citations for each original paper from Google Scholar 
on 7 September 2019, as a proxy for use. We then 
calculated the number of citations for each whole year 
since publication. To retain awareness of the context 
of their initial design and aims, we summarised index 
updates separately from the original papers.
Data collection process
We created a data extraction tool containing specific 
elements of interest for each original index. This tool 
took account of previous reviews on this topic as well 
as additional information relating to mental health. We 
used a broad definition of mental health, comprising any 
mental disorder, including mood disorders, dementia, 
delirium, and addictions as well as relevant symptoms. 
Many papers describe validation of the indices used so 
details on the size and demographic distribution of the 
populations under test was important.
Two authors independently extracted data from all full 
texts. We compared the consistency of extracted items 
and resolved any differences by discussion and reference 
to the original paper, with a third author available in case 
of substantially differing data extraction.
Data items
The variables of interest during data extraction were 
first author, year of publication, and name of index; 
original purpose of the index; characteristics of the 
population under test, including type of data source 
(eg, cohort study), location, number of participants, sex 
and age distribution, and mean number of concurrent 
medical conditions (when given); components in­
cluded in the index; weighting method (if any) 
and details of model for its development; outcome 
measures; information and resources required to 
apply the index; internal validation or comparison 
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with another index (if applicable); external validation 
and performance compared with another index (if 
applicable); and inclusion of mental health (either in 
comorbidities or as outcomes).
risk of reporting bias in original studies
We assessed the risk of bias of study design and reporting 
and aimed to develop overall recommendations for 
index choice. The Cochrane Collaboration advises 
against scales that generate total numerical scores, 
preferring emphasis on individual papers’ performance 
on each criterion.9 After our search date the Prediction 
model Risk Of Bias ASsessment Tool (PROBAST) was 
published. It focuses on risk of bias and applicability 
in prediction model studies.10 As our search was not 
restricted to prediction models, it was not appropriate 
to apply this tool to every paper. We therefore developed 
our own list of criteria having referred to resources 
available for assessing clinical prediction indices.11­13 
Our assessment aimed to deal with risk of selection, 
observer, and funding bias. The list contained 10 
questions on the population tested, description of the 
index, statistical methods, validity, and funding. The 
assessment tool is available in the appendix (appendix 
eTable 2), including division into domains. We also 
included an overall impression of the papers’ risk of 
bias based on the Scottish Intercollegiate Guidelines 
Network standard, which was scored separately to 
the criteria rather than in an additive fashion.14 Two 
reviewers independently assessed each paper and 
resolved disagreements by discussion.
When choosing an index, its predictive ability 
and its use elsewhere are important. We generated 
overall recommendations taking into account 
the generalisability of participants, selection and 
clinical relevance of index components, outcome 
measurement, risk of reporting bias, and model 
evaluation. These were separated into three main 
categories: recommended, potentially useful (usually 
when indices were applicable to certain situations), 
and not recommended.
synthesis of results
We anticipated finding a wide variety of indices 
covering diverse outcome measures and therefore 
planned to summarise these narratively. Because of 
the range of outcomes included we did not expect to be 
able to perform meta­analysis. We listed performance 
and validity statistics as reported by the original 
papers or validation studies alongside each other, for 
comparison.
We did not expect to find indices specifically 
designed for measuring physical multimorbidity in 
relation to any aspect of mental health. Therefore, for 
separate narrative synthesis we planned to seek those 
indices that mentioned mental illnesses or symptoms, 
either as comorbidities or as outcomes.
Patient and public involvement
An early draft of this paper was discussed with a 
lay contributor who has personal experience of 
multimorbidity. We incorporated her comments into 
the text—for example, noting in the introduction that 
the number of conditions a person has might not reflect 
their experience of health, and in the discussion her 
suggestions about outcomes that could be important to 
patients. The lay contributor also commented on a lay 
summary of the paper (see appendix page 43), which 
we amended accordingly.
results
study selection
The searches yielded 7128 results. A search of 
bibliographies and citations identified 48 additional 
relevant titles, and a further 15 titles were added from 
the list of indices mentioned in excluded abstracts. The 
total number of titles was therefore 7191. Duplicates 
were removed using EndNote X8 and Covidence 
software,8 15 leaving 5560 unique records for screening 
(fig 1).16 Overall, 5236 titles were excluded at the 
screening stage, leaving 324 abstracts for eligibility 
assessment. Of these, 86 full texts were assessed and 
35 papers finally included.
study characteristics
Twenty articles originated from the United States17­36; 
three from Australia37­39; two each from the United 
Kingdom,40 41 Taiwan,42 43 and Italy44 45; and one each 
from Canada,46 Spain,47 Germany,48 New Zealand,49 
Norway,50 and India.51 They were published between 
1968 and 2017, with 15 (43%) published since the last 
systematic review on this topic in 2009.17­20 40 42­51 The 
mean number of participants included in the derivation 
populations of indices developed after 2009 was 
356 906, compared with 75 491 before 2009. The newer 
indices primarily required access to medical records in 
11 (73%) cases,18­20 40 42­45 47­49 and the remainder (4, 
27%) self­report17 46 50 51; 10 (50%) indices before 2009 
primarily used medical records21 23 26 29 32­36 39 and 10 
(50%) used self­report.22 24 25 27 28 30 31 37 38 41
The majority of papers described one final 
multimorbidity index, even if they tested various 
models in development, and four papers concluded 
with more than one index or measure.23 25 30 46 For 
consistency, when articles were summarised and their 
quality assessed we considered each paper as a whole 
and noted when more than one index existed. We did 
not comment on models that used only unweighted 
disease counts, in keeping with our overall exclusion 
criteria.
index components
Four indices primarily used weighted drug counts 
to quantify multimorbidity,33 39 43 45 five used 
diagnostic groups or clusters,23 26 34 36 48 and 25 
included counts of diseases. Of these, 21 were 
weighted17 19 20 22 24 27­29 31 32 35 37 38 40 41 44 46 47 49 50 51 
and nine incorporated other parameters, demographic 
or otherwise.18 19 22 25 28 30 42 47 51 Four papers 
used a combination of weighting and additional 
variables.19 22 28 47 One index used physiological 
measurements to diagnose multimorbidity.21 When 
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diagnoses were required, 14 indices took these from 
medical records18 19 20 23 26 29 32 35 36 40 42 44 48 49 and 15 
from self­report.17 22 24 25 27 28 30 31 36 37 38 41 46 50 51Figure 2 
is a spider diagram of the papers, displayed according 
to their broad category of index components.
Outcome measures
The number of outcomes assessed in each paper 
ranged from none to seven. Eighteen studies measured 
mortality as an outcome,19 21 22 25 28 29 33 35­40 42 44 45 47 49 
13 aimed to predict hospital admissions,18 23 28 
31 33 37­39 42­45 49 10 measured general healthcare 
use,18 19 23 25 27 31 33 34 38 46 seven measured 
independence with daily activities or disability (with 
or without physical functioning),19 21 24 31 33 38 41 seven 
measured health related quality of life,20 25 27 37 38 46 48 
five measured overall self­reported health,24 33 41 46 50 
five measured healthcare costs,23 26 27 30 44 and four 
measured drug use.19 23 27 46 Mental health was a 
specific outcome in three papers,24 33 41 with a further 
six including mental health aspects of established 
tools (eg, the mental component score of SF­ 
36).20 25 27 37 38 48 Adherence to screening 
programmes,18 specific physiological parameters,18 
and care quality indicators19 were assessed by one 
tool each. Ten (29%) papers used cross sectional 
data to derive their index weighting but measured 
longitudinal outcomes.19 21 22 25 33 36 38 39 42 43 Table 1 
lists the papers according to their original outcomes 
and index components.
applicability
The applicability of each index depends on study 
design and intended usage. Table 1 summarises 
index components and outcome variables. Most of 
the original papers (27, 77%) contained sufficient 
information for readers to use the index, usually 
with lists of included conditions with or without 
weighting. Of the remainder, access to additional free 
resources was needed in four,30 43 45 47 information 
from proprietary scales was needed in one,51 and two 
were missing information that would allow the index 
to be applied.18 31 One index was only available as 
proprietary software.34 52
Some of the indices, although designed to measure 
multimorbidity, were developed in cohorts of people 
Full texts excluded
Did not refer to an index
Referred to an existing index
Conference abstracts
Referred to an index disease
Full text not available in English
21
18
8
3
1
Records identified through database searching
Medline
Web of Science Core Collection
Cochrane Library
Embase
PsycINFO
Scopus
CINAHL Plus
3102
98
906
393
21
166
2442
Additional records identified through
bibliography and citation tracking
7128
Titles excluded
Records screened aer duplicates removed
63
5560
Abstracts assessed for eligibility
5236
Abstracts excluded
324
Full text articles assessed for eligibility
238
86
Studies included in qualitative synthesis
35
51
fig 1 | screening process according to Prisma
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with a specific disease, and therefore this condition was 
not included in the list of comorbidities.23 31 Most indices 
were based on diagnoses or drugs, but two indices 
required results of laboratory or other investigations.21 47
The provenance of papers will affect their 
applicability to other settings. For example, the 
majority of papers came from the US where the 
predominant health system is commercial and 
healthcare costs are of interest to insurers. Some of the 
indices were designed with a particular population in 
mind, such as the questionnaire for Indian primary 
care. This included diseases that are less prevalent 
in other geographical areas, such as filariasis and 
tuberculosis, which might limit generalisability.51 
Other original indices have domains that might be 
outdated. One example is the Charlson comorbidity 
index.35 This index assigns the maximum weight of 6 
points to AIDS, but the life expectancy for HIV/AIDS in 
high income countries has changed considerably since 
the index’s publication in 1987.53
Although several papers mentioned outcomes 
as relevant to patient experience, only one clearly 
described involving patients in the study design, by 
developing their rating scale with focus groups.37
summary of evidence
Appendix eTables 3 to 6 summarise all included 
papers according to their index’s original purpose, 
components and outcome variables, and information 
used. The data source, location, and demographics 
of the population used to derive or test the measure 
are listed as they are relevant for context. Our overall 
recommendations are also included. In appendix 
eTable 3, the index components are weighted condition 
counts, in appendix eTable 4, the index compo­
nents are conditions with additional parameters, 
in appen dix eTable 5 they are weighted drug counts, 
and appendix eTable 6 comprises the remain­
der, including diagnostic groups and physiological 
measures.
Sangha et al27
Greenfield et al31
Crabtree et al41
Byles et al37
Bayliss et al24
Lee et al22*
Charlson et al35
Bernabeu-Wittel et al47*
Carey et al40
Fan et al28
Selim et al25
Wen et al42
Linn et al36
Brettschneider et al48
Pope et al26
Starfield et al34
Farley et al23
Newman and Goodman21
Corrao et al44
Stanley and Sarfati49
Desai et al29
Lorem et al50
Parkerson et al32
Min et al19
Hong et al18
Pati et al51
Lee et al22*
Fan et al28
Hornbrook and Goodman30
Conditions
Tooth et al38
Healthcare use, functional
ability, health related
quality of lifeHospital admission
Self-rated health, quality
of life, drug use,
depression scale
Body mass index,
sex, functional
difficulty
Self-rated
Rated by
clinician
Weighted
Age
Symptoms
Health related quality
of life measures
Physician
rated severity
Disability status,
Medicaid entitlement
Activities of daily living
indices, hospital admissions,
haemoglobin
Clusters or
categories
By severity or
symptoms
Smoking status and
treatment adherenceOther demographic, clinical and
payment/utilisation information
Robusto et al45
Dong et al43
According to outcomes
in development set
Smoking
status
Rated for
level of
abnormality
Functional
status
Self-reported health
Combined
with
Quality of life
Bernabeu-Wittel et al47*
Pre-defined
by experts
Mortality
Disability
Hospital admission
According to
expert consensus
According to
previous studies
According to
outcomes in
development set
Mukherjee et al20
Wei et al17
George et al39
Von Korff et al33
Wister et al46Multimorbidity
measures
Physiological
measures Drugs
Disease stability,
prognostic
information
Hospital visits, physician
claims, prescriptions
Mortality
Weighted
Weighted
Combined with
Demographics
fig 2 | spider diagram summarising index components. *Paper appears under more than one category
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weighting
The majority of indices (n=29, 83%) included some 
form of component weighting. Conditions, diagnostic 
categories, and drugs were weighted by severity 
or symptoms, either self­reported or defined by 
clinicians, or according to their associated outcomes 
in a derivation cohort. Different methods were used for 
developing each index, and disparities existed in the 
level of methodological detail reported. The appendix 
eTable 7 summarises the method for developing each 
model, the details provided, and baseline outcome 
reporting.
inclusion of mental health
Twenty nine (83%) of the papers contained some 
measure of mental health or dementia, with 18 of 
these including mental health markers exclusively as 
comorbidities (including psychotropic drugs when 
table 1 | studies classified by components and outcomes of original versions of indices
Original  
outcomes
index components
conditions
Drugs  
(all weighted)
categories or clusters
Physiological 
measuresweighted
with additional  
parameters weighted
with additional 
parameters
mortality Corrao et al44 Wen et al42 Robusto et al45 Linn* et al36 Newman* et al21
Stanley and Sarfati49 Min et al19 George et al39
Min et al19 Bernabeu-Wittel et al47 Von Korff* et al33
Carey et al40 Lee* et al22
Bernabeu-Wittel et al47 Selim et al25
Tooth et al38 Fan et al8
Lee* et al22
Byles et al37
Fan et al28
Desai* et al29
Charlson* et al35
Healthcare use and costs Corrao et al44 Hong et al18 Von Korff* et al33 Pope* et al26 Farley et al23
Wister et al46 Min et al19 Starfield* et al34
Min et al19 Selim et al25
Tooth et al38 Hornbrook and Good-man30
Sangha* et al27
Greenfield* et al31
Hospital admission Corrao et al44 Wen et al42 Robusto et al45 Farley et al23
Stanley and Sarfati49 Hong et al18 Dong et al43
Byles et al37 Fan et al28 George et al39
Fan et al28 Von Korff* et al33
Greenfield* et al31
independence or disability Min et al19 Min et al19 Von Korff* et al33 Newman* et al21
Tooth et al38
Bayliss* et al24
Crabtree et al41
Greenfield* et al31
self-rated overall health Lorem et al50 Von Korff* et al33
Wister et al46
Bayliss* et al24
Crabtree et al41
Health related quality of life 
or life satisfaction
Wister et al46 Selim et al25 Brettschneider et al48
Mukherjee* et al20
Tooth et al38
Byles et al37
Sangha* et al27
Drug use Wister et al46 Min et al19 Farley et al23
Min et al19
Physical functioning Bayliss* et al24 Newman* et al21
Greenfield* et al31
mental health, depression  
or anxiety
Bayliss* et al24 Von Korff* et al33
Crabtree et al41
Greenfield* et al31
specific physiological  
measures Hong et al
18
Quality indicators or  
adherence to screening
Min et al19 Hong et al18
Min19
no outcomes measured Wei et al17 Pati et al51
Pati et al51
Parkerson* et al32
*Studies have been subsequently updated or adapted.
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relevant)17­19 22 26 30 32 34­36 39 40 42 43 45 47 49 51 and three 
including mental health markers as an outcome 
only.24 31 33 Seven measures included different 
aspects of mental health as both comorbidities and 
outcomes,20 25 27 37 38 44 48 and one paper included 
anxiety and depression as both a comorbidity and 
an outcome.41 In appendix eTable 8, we summarise 
whether each index dealt with aspects of mental 
health, as either comorbidities or outcomes, and how 
these were measured. Where papers discussed specific 
findings relating to multimorbidity and mental health, 
we present their conclusions.
risk of reporting bias within studies
Using our quality assessment tool, we classified six 
papers as high quality with little or no risk of bias in 
reporting22 24 27 32 37 49 and seven as low quality with 
moderate to high risk of bias.23 28 34 35 36 41 42 The 
remaining 22 papers were of satisfactory quality. Of 
the five domains we assessed, the best reported were 
index description and funding source. Validity and 
statistical methods were the least well reported across 
all papers. Table 2 shows the scores for all papers 
across each domain. As we had agreed in advance to 
judge the overall impression without summing domain 
scores, the domain scores did not always lead to the 
same overall impression. For example, one study was 
given an overall impression of satisfactory with a total 
domain score of 6,48 whereas another study scored 8 
and was also deemed satisfactory.51
risk of bias across studies
It was not possible to quantify publication bias owing 
to the variety of methods and outcomes used. It is 
likely that more unpublished methods of measuring 
multimorbidity exist and are used in clinical practice, 
especially tailored to specific patient populations or 
available clinical information.
usage, performance, and validation
As a proxy for usage, we calculated the number of 
annual citations for each paper. The number of citations 
for each year since publication ranged from three41 to 
949,35 with a median of 8.8 (interquartile range 5.3­
16.2). This information is listed alongside measures 
of the indices’ performance at predicting outcomes 
and validation in appendix eTables 9 (indices without 
external validation) and 10 (externally validated 
indices). Sixteen original papers described designing 
indices within a derivation cohort and testing their 
ability to predict specific outcomes within a separate 
validation set.20 22 28­30 33 35 37 38 40 43 44 45 47 49 50
Fourteen original papers measured an index’s 
performance at predicting outcomes17 22 28 30­32 34 36­
38 41 42 46 48 and 20 compared an index to an existing 
measure of multimorbidity.18­21 23­27 29 33 35 39 40 43 44 
45 47 49 50 Fourteen indices were validated elsewhere, 
of which 11 were compared with other indices20 22 
26 27 33­36 39 43 47 and three only measured ability to 
predict outcomes.17 24 32 Among the indices that were 
externally validated, 11 were tested at predicting 
different or additional outcomes to those in the original 
index design.20 24 26 32­36 39 43 47 Some indices were tested 
against other indices that had been developed with 
different original outcomes—for example, the Charlson 
index where the outcome in question was admission to 
hospital43 or health related quality of life.20
updates and adaptations
Thirteen (37%) of the indices had updates or adap­
tations published, by either original or separate 
research teams. These revised versions included 
updated comorbidities or weights, focused on specific 
patient groups, or mapped a clinical index to codes 
for administrative data. Two of the indices are risk 
adjustment methods undergoing regular review and 
updates.26 34 The relevant indices are listed in appendix 
eTable 11 alongside a summary of their adaptations 
and updates and any reported performance metrics. 
The older and widely used indices such as Charlson, 
Chronic Disease Score, and Cumulative Illness Rating 
Scale have been adapted and updated many times; we 
include the most cited versions. Most updated indices 
are broadly based on the aim and outcome measures of 
the original, with some exceptions.57­60
Of the indices that were not updated, in some cases 
this was because the original index was unsuccessful 
at predicting specific outcomes37 or was not designed 
for use outside of the original study.30
discussion
In this review we collated descriptions of 35 distinct 
multimorbidity indices. The papers were diverse 
in study design, intended purpose, and variables 
included. Similarities did, however, emerge, such 
as index components concentrating on conditions, 
diagnostic categories, drug classes, or physiological 
measures. Mortality was the most commonly studied 
outcome, with healthcare use, hospital admission, 
functional ability, and health related quality of life as 
other important groups. Those that measure mortality 
will be of most relevance to clinicians and researchers, 
whereas healthcare use and costs are more useful 
to healthcare providers and funders, particularly 
in predominantly private healthcare systems. For 
patients, the most relevant outcomes might be quality 
of life or self­reported health.
strengths and weaknesses of this study
A major strength of this review was the use of an 
updated search in a rapidly expanding area of re­
search and a focus on multimorbidity measures that 
specifically include mental health.
Although the medical subject heading (MeSH) term 
“comorbidity” has existed since 1990, a new MeSH 
term, “multimorbidity,” was introduced in January 
2018, after our search had been designed and pre­
registered.1 61 We found that the word “indexes” was 
used in some titles when we had used “indices” in 
our search terms. One paper was found by citation 
tracking and had apparently been missed during our 
search because we had omitted the term “score.”44 
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However, we aimed to minimise the number of missed 
relevant papers by searching bibliographies, citations, 
and indices that had been mentioned in the abstracts 
we excluded. A limitation of this review is that we 
limited our search to full texts in the medical literature, 
excluding conference abstracts and other grey 
literature. This approach might have missed indices 
in clinical use that are either unpublished or based on 
guidelines from healthcare quality institutions.
In this review, we excluded papers that used simple 
counts of conditions to measure multimorbidity, 
focusing instead on indices. We chose to make this 
distinction because indices tend to include multi­
ple parameters to quantify different aspects of 
multimorbidity and use sophisticated models to predict 
outcomes. However, as disease counts are the most 
commonly used method of measuring multimorbidity, 
their exclusion is a limitation of our work.4 The ease of 
applying disease counts means they are frequently used 
and they are comparable between studies as long as the 
list of candidate conditions is clear.62 One paper in this 
review reported that a count of diagnosis clusters was 
a better predictor of healthcare expenditure than more 
complex indices.23 Other research has drawn similar 
conclusions.63 64 Reviewing the use of disease counts is 
outside the scope of this paper and has been discussed 
elsewhere.65­67 Simple counts of drugs have also been 
shown to predict healthcare use and mortality,68 and 
using these or disease counts are more practical than 
indices in many settings. For example, they are used 
in clinical care, as they do not require calculations 
or particular software, or in large population studies 
where the impact of each condition on individuals is 
unknown.6
As this review is aimed at those undertaking 
population or community research, we also exclu­
ded studies of people who had been admitted to 
hospital or live in residential care. This meant that 
several commonly used indices were not included in 
this review, such as the Elixhauser index.69 We did 
include the Charlson, PROFUND, Self­Administered 
Comorbidity Questionnaire, and High­Risk Diagno­
ses for the Elderly Scale indices as although the 
studies recruited hospital patients, they did so when 
the patients were discharged, and the main period of 
interest was later, in the community setting.27 29 35 47
Some of the indices have been in use for many years 
and have several adaptations. The Charlson index is the 
most widely known and warranted its own systematic 
review within a medical specialty (critical care)70; we 
table 2 | Overall risk of reporting bias: domain scores
reference
sample selection 
(maximum++)
index description 
(maximum ++)
statistical methods 
(maximum ++)
validity  
(maximum +++)
funding source 
(maximum ++) Overall quality
Corrao et al44 - ++ + + ++ Satisfactory
Wen et al42 ++ ++ + - ++ Low
Stanley and Sarfati49 ++ ++ + + ++ High
Wei et al17 + ++ + + ++ Satisfactory
Robusto et al45 + ++ + + ++ Satisfactory
Lorem et al50 + ++ ++ + ++ Satisfactory
Pati et al51 ++ ++ + ++ ++ Satisfactory
Hong et al18 ++ ++ + + ++ Satisfactory
Wister et al46 ++ + ++ - ++ Satisfactory
Brettschneider et al48 ++ ++ + - ++ Satisfactory
Min et al19 - ++ + ++ + Satisfactory
Carey et al40 + ++ + + ++ Satisfactory
Dong et al43 + ++ + + ++ Satisfactory
Bernabeu-Wittel et al47 ++ ++ + + ++ Satisfactory
Mukherjee et al20 ++ ++ + + ++ Satisfactory
Newman and Goodman21 ++ ++ + + ++ Satisfactory
Tooth et al38 + ++ + + ++ Satisfactory
George et al39 - ++ + ++ + Satisfactory
Lee et al22 ++ ++ + + ++ High
Farley et al23 - - + + + Low
Byles et al37 ++ ++ + + - High
Bayliss et al24 ++ ++ ++ + ++ High
Selim et al25 + ++ + + ++ Satisfactory
Pope et al26 ++ ++ + + ++ Satisfactory
Sangha et al27 ++ ++ + +++ ++ High
Fan et al28 + + + + ++ Low
Desai et al29 ++ ++ + + ++ Satisfactory
Crabtree et al41 - ++ + + ++ Low
Hornbrook and Goodman30 + + + + ++ Satisfactory
Greenfield et al31 ++ ++ + + ++ Satisfactory
Parkerson et al32 ++ ++ + ++ + High
Von Korff et al33 - + + ++ ++ Satisfactory
Starfield et al34 - ++ - + ++ Low
Charlson et al35 - ++ + + - Low
Linn et al36 - + + ++ - Low
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have only briefly summarised its performance and the 
principal adaptations. More information is available in 
another systematic review on this topic.71
Some of the indices were specifically designed 
for use with administrative data. These might have 
scored more poorly on quality assessment as our tool 
focused on reporting and clinical applicability. Our 
search also included papers that compared different 
measurements of multimorbidity but that were 
not intended for clinical use.46 We included these 
papers for completeness when they met our inclusion 
criteria. We aimed to find measures of multimorbidity, 
and our exclusion criteria included studies of 
comorbidity with a specific index disease. However, 
in two of the papers studied the indices had been 
developed in populations with one condition only, 
either hypertension23 or type 2 diabetes.31 We referred 
to our protocol and included these studies because 
their aim was to study multimorbidity rather than 
comorbidities of those conditions as index diseases. 
These papers are, however, less generalisable to the 
general population.
Our search was intentionally broad, using a wide 
range of search terms in multiple medical research 
databases. We included a variety of studies measuring 
multimorbidity from different perspectives, which is a 
strength over previous more specific reviews.71
We generated overall impressions of the risk of 
reporting bias and recommendations for index use, 
to provide a guide for researchers when choosing an 
index. Samples in the included studies were, however, 
heterogeneous, and the indices had varied purposes 
and components. Therefore, our recommendations 
are subjective. Formally comparing the predictive 
ability of the indices is outside the scope of this work 
but has been comprehensively performed by other 
investigators.68 72­74
comparison with previous literature
The two most recent similar systematic reviews 
to ours did not formally assess the quality of 
publications.34 Fifteen (43%) of the indices we 
included were published after 2009 and therefore 
would not have been found by the searches in these 
previous reviews. This is out of proportion to the 
increase in multimorbidity publications since 2010, 
suggesting that many recent papers have used 
either older measures or disease counts.2 A newer 
systematic review on this topic focused only on tools 
used on administrative data and conducted its search 
in 2012.71 A systematic review of multimorbidity 
systematic reviews, published in 2018, focused 
on definitions and measurement.5 However, it did 
not include a search for new indices, thereby also 
omitting the 15 papers published since 2010.
recommendations for index selection
We suggest that to select an index for clinical or 
research use, clinicians or researchers should first 
consider their desired outcomes and the information 
available. Box 1 summarises the process of selecting 
an index using this review.
Appendix eTables 3­6 list our overall recommendations, 
divided broadly into “not recommended,” “potentially 
useful,” and “recommended,” and figure 3 displays the 
12 indices that we recommend according to their design. 
The 10 indices that are not recommended could be 
useful for other purposes, such as recording symptoms41 
or comparing models,37 but our recommendations focus 
on those that are practical for designing multimorbidity 
research.
box 1: guide to selecting an index using this paper when designing a 
multimorbidity study
•	Identify reasons for including multimorbidity—for example, is multimorbidity 
important because of its association with quality of life or mortality? This will inform 
which outcomes of original indices are relevant
•	Identify the exposure variables available (eg, diagnoses, drugs)
•	Identify the outcomes to be measured
•	Use figure 3 to choose a recommended index
•	Use the information in the appendix (eTables 9 and 10) to compare usage and 
performance of any suitable indices
Desai et al29
Charlson et al35*
Tooth et al38
Mukherjee et al20
Tooth et al38
Tooth et al38
Mortality Health related
quality of life
   Healthcare use,
daily functioning
Self-rated health
Physical
functioning,
depression,
self-efficacy
Mortality
Hospital admission
Hospital admissionHealthcare costs
With additional information
Diagnoses
Available information
Drugs
Original outcomes
Mortality
Disease severity,
self-rated health
Lorem et al50
Bayliss et al24
Bayliss et al24 Pope et al26 Lee et al22
Fan et al28
Fan et al28 Dong et al43
Robusto et al45
Von Korff et al33*
Robusto et al45
Von Korff et al33*
Von Korff et al33*
fig 3 | flowchart of recommended indices organised by components and original outcomes
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conclusions
At least 35 objective measures of multimorbidity are 
available for people living in the community, and each 
of these uses different variables to generate a score or 
index, linked with various or no outcome measures. 
We found no specific index for investigating the 
interplay between mental and physical multimorbidity, 
although this issue is dealt with in a variety of ways 
across the measures. The array of index components 
and outcomes means that a validated measure exists 
for many applications, including clinical, research, 
and cost prediction. It is important when choosing 
an index to consider its original purpose and the 
outcomes for which it is validated. Given the differing 
methodologies of multimorbidity research, it would 
not be appropriate to assume that a single index could 
definitively measure multimorbidity in all settings. 
However, with this research area at risk of saturation, 
we propose that anyone measuring multimorbidity 
should study existing indices before developing new 
ones.
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